Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I

Afroza Sultana1, Blake J Cochran1, Fatiha Tabet1

  • 1Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Australia, Sydney, New South Wales, Australia; and.

Insights

Apolipoprotein A-I (apoA-I) inhibits inflammatory signaling in adipocytes by blocking Toll-like receptor 4 (TLR4) activation of MAPKs and NF-κB, offering potential therapeutic strategies for obesity-related metabolic disorders.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Metabolic Research

Background:

  • Obesity is linked to metabolic disorders through inflammatory signaling pathways.
  • Toll-like receptor 4 (TLR4)-mediated activation of MAPKs and NF-κB are key inflammatory pathways in obesity.
  • Apolipoprotein A-I (apoA-I) has anti-inflammatory effects on adipocytes, but its impact on these specific signaling pathways is unclear.

Purpose of the Study:

  • To investigate if apoA-I inhibits MAPKs and NF-κB activation in mouse 3T3-L1 adipocytes.
  • To determine if apoA-I's inhibitory effects are dependent on the ATP binding cassette transporter A1 (ABCA1).

Main Methods:

  • Differentiated 3T3-L1 adipocytes were incubated with apoA-I.
  • Cell surface expression of TLR4 and myeloid differentiation primary response 88 (MyD88) were measured.
  • Activation of MAPKs (ERK, p38MAPK, JNK) and NF-κB (p65 subunit nuclear localization) were assessed in lipopolysaccharide (LPS)-stimulated cells.

Main Results:

  • ApoA-I decreased TLR4 and MyD88 expression in an ABCA1-dependent manner.
  • ApoA-I inhibited MAPK activation and pro-inflammatory adipokine expression, dependent on ABCA1.
  • ApoA-I suppressed NF-κB nuclear localization independently of ABCA1.

Conclusions:

  • Apolipoprotein A-I inhibits TLR4-mediated inflammatory signaling pathways in adipocytes.
  • This inhibition involves preventing MAPK activation and, independently, NF-κB activation.
  • The findings suggest apoA-I's potential role in mitigating obesity-induced inflammation.

Related Concept Videos

Inflammation01:38

Inflammation

Overview
64.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
576